The stakes of this question are far from academic. Fluoroquinolones, including drugs such as levofloxacin and moxifloxacin, form the backbone of the shorter, all-oral treatment regimens that the World Health Organization now endorses for patients whose tuberculosis does not respond to rifampicin, a key first-line antibiotic. When a physician knows that a patient’s tuberculosis strain is susceptible to fluoroquinolones, a shorter regimen becomes a realistic option, sparing the patient months of toxic therapy. When the strain is resistant, that regimen would fail, and an alternative must be assembled. The problem is that in many of the places where drug-resistant tuberculosis burdens are heaviest, laboratory capacity for rapid drug susceptibility testing—the gold standard for detecting resistance—is limited or absent, leaving clinicians to make consequential decisions with incomplete information.

Prediction models have emerged as one proposed bridge across this diagnostic gap. The idea is elegant in principle: by feeding routinely collected patient information—age, sex, treatment history, comorbidities, social risk factors—into a statistical algorithm, a model could estimate the probability that a patient’s tuberculosis is already resistant to fluoroquinolones, even without laboratory confirmation. Clinicians could then weigh that probability when selecting a regimen, much as they weigh other forms of clinical judgment. But most prediction models in this field have been developed and evaluated within a single country, using data from one health system and one circulating population of tuberculosis strains. Whether such models generalize to different epidemiological settings has remained an open and largely untested question.

To answer it, the research team—Tianfang Shao, Mariana R. Neves, Molly Franke, Carole Mitnick, Jennifer Furin, Ted Cohen, and Reza Yaesoubi—turned to the TB Portals, an open-access data-sharing platform curated by the National Institute of Allergy and Infectious Diseases. From this resource, they assembled records for 5,175 patients with rifampicin-resistant tuberculosis who had documented fluoroquinolone drug susceptibility testing results, drawn from eight countries: Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Romania, and Ukraine, with data collected between 2012 and 2024. The burden in this cohort was substantial: 1,772 patients, or 34.2 percent, carried tuberculosis strains that were already resistant to fluoroquinolones. That high prevalence reflects both the severity of the drug resistance epidemic in Eastern Europe and Central Asia and the clinical urgency of identifying resistant cases before committing patients to a regimen that depends on these drugs.

Methodologically, the study was designed to stress-test generalizability in a way that few previous analyses have attempted. The researchers built prediction models using three distinct algorithms spanning a range of complexity: logistic regression, a transparent and widely used statistical technique; neural networks, which can capture intricate nonlinear relationships among predictors; and XGBoost, a gradient-boosted decision tree method that has become a favorite in clinical prediction research for its flexibility and performance. Each algorithm was then evaluated under three different training and validation strategies. The first strategy pooled data from all eight countries to train a single multi-country model. The second trained and tested models within individual countries using internal validation. The third—and most revealing—trained models on data from a subset of countries and then externally validated them on countries deliberately held out of training, simulating exactly what happens when a model built elsewhere is imported into a new setting.

Model performance was quantified using two standard metrics. The area under the receiver operating characteristic curve, or AUROC, measures how well a model separates resistant from susceptible cases across all possible decision thresholds, with 0.5 representing chance performance and 1.0 representing perfect discrimination. The area under the precision-recall curve, or AUPRC, is often considered more informative when the outcome of interest is relatively uncommon, because it focuses on how precisely the model identifies true positive cases. The pooled, multi-country models achieved what the authors describe as moderate discrimination after optimism correction, with AUROC values ranging from 0.70 to 0.72 and AUPRC values from 0.57 to 0.59 across the three algorithms. In practical terms, such models carry real information, but they would misclassify a substantial fraction of patients if used alone to route individuals toward or away from fluoroquinolone-based regimens.

Within-country models performed somewhat better, with AUROC and AUPRC values reaching 0.8 for some countries, suggesting that locally trained models can extract more signal from their own patient populations than a globally pooled model can. The cross-country external validation, however, exposed the fragility of geographic transfer. When a model trained on external data was applied to a held-out country, the loss in performance ranged from negligible to more than 0.1 in AUROC or AUPRC, depending on the country and the algorithm involved. A drop of that magnitude is clinically consequential: it can mean the difference between a model that usefully flags resistant infections and one that generates enough false reassurance to steer patients toward regimens destined to fail. The variability across settings indicates that no single number can capture how well a model will travel, and that each new deployment demands its own rigorous evaluation.

Just as striking as the performance differences were the differences in which predictors mattered. A limited set of variables—chiefly those related to the case definition and to a patient’s treatment history—emerged as the most consistently informative predictors across countries and algorithms. This makes biological and epidemiological sense: patients who have been treated for tuberculosis before, particularly with fluoroquinolones or other second-line drugs, face a higher likelihood of harboring strains that have already evolved resistance. By contrast, demographic characteristics, comorbidities, social risk factors, education, and employment variables contributed far more inconsistently, with their predictive weight swinging widely across countries and modeling approaches. This instability suggests that the social and structural determinants of drug resistance are woven into local contexts in ways that a model trained elsewhere cannot simply assume.

The authors are careful to note an important limitation of their analysis. The incidence of rifampicin-resistant tuberculosis and of fluoroquinolone resistance was relatively stable across the years represented in their dataset, which means their findings may not extend to settings where the dynamics of multidrug-resistant tuberculosis are changing markedly—for example, where new regimens are rapidly reshaping patterns of resistance. Prediction models are, at their core, pattern-recognition devices calibrated to the populations and time periods that produced their training data, and shifts in transmission, treatment practices, or drug exposure can quietly invalidate the relationships a model has learned. Any real-world deployment would therefore need ongoing monitoring and periodic recalibration, not just a one-time validation.

The study’s conclusions carry a clear message for the field of tuberculosis care and for clinical prediction modeling more broadly. Predicting fluoroquinolone resistance from demographic and clinical characteristics is feasible to a moderate degree, and locally developed models can offer meaningful support to clinicians working without rapid laboratory testing. But models developed for one country, or even for several countries pooled together, cannot be assumed to perform elsewhere without rigorous external validation in the destination setting. As all-oral, shorter regimens spread across the globe and diagnostic capacity lags behind, the researchers argue that the path forward lies in locally informed prediction models—tools built and validated on the populations they are meant to serve—rather than in the export of algorithms whose accuracy quietly dissolves at national borders.

Subject of Research: Cross-country validation of prediction models for fluoroquinolone resistance in rifampicin-resistant tuberculosis

Article Title: Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study

Article References: Shao, T., Neves, M. R., Franke, M., Mitnick, C., Furin, J., Cohen, T., & Yaesoubi, R. (2026). Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study. PLOS Medicine, 23(9), e1004965. https://doi.org/10.1371/journal.pmed.1004965

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1004965

Keywords: tuberculosis, fluoroquinolone resistance, rifampicin-resistant tuberculosis, prediction models, drug susceptibility testing, machine learning, XGBoost, external validation, TB Portals, WHO treatment regimens, multidrug-resistant tuberculosis, clinical decision-making

NorA belongs to the major facilitator superfamily, one of the largest classes of secondary active transporters found across all domains of life. These proteins move substrates across the membrane by coupling transport to the proton motive force, alternating between inward-facing and outward-facing states through a rocking-bundle mechanism. In S. aureus, NorA exports a broad range of amphiphilic cations, including fluoroquinolones such as ciprofloxacin and norfloxacin, as well as biocides and dyes. When NorA is overexpressed, bacteria can tolerate antibiotic concentrations many times higher than those that kill susceptible strains, contributing to the multidrug-resistant phenotypes that complicate treatment of methicillin-resistant S. aureus infections.

For decades, chemists have sought NorA inhibitors as potentiators of fluoroquinolone therapy. Early leads, including the plant alkaloid reserpine and its analogs, demonstrated that chemical blockade of the pump could resensitize resistant bacteria, but these compounds suffered from poor potency, toxicity, and lack of selectivity. More recently, optimized inhibitors derived from diverse scaffolds have shown improved activity in vitro and in infection models. What remained missing was a molecular picture of how such compounds engage NorA and why their binding prevents transport. The new study addresses this gap by combining structural biology with functional and computational analyses to reveal the inhibitor-bound states of the pump.

Using cryo-electron microscopy, the team determined structures of NorA in complex with several representative inhibitors. The structures capture the transporter in distinct conformations along its transport cycle, showing that the small molecules do not simply plug the substrate pathway in a single orientation. Instead, each inhibitor stabilizes a particular global arrangement of the protein, locking the bundle and core domains in configurations that cannot proceed to the next step of the alternating-access mechanism. This conformational trapping explains how chemically diverse compounds achieve functional blockade: by raising the energetic barriers between states, they freeze the pump mid-cycle and prevent the coordinated movements required for proton-coupled antibiotic export.

The structural data reveal a central, amphipathic binding cavity within the membrane domain, bounded by helices that undergo the largest rearrangements during transport. Inhibitors occupy this cavity with their cationic or polarizable groups positioned near residues that normally participate in proton transfer and substrate recognition, while hydrophobic moieties pack against the helical walls. Comparisons among inhibitor-bound structures show that subtle differences in ligand shape and charge distribution shift the equilibrium toward inward-facing, occluded, or outward-occluded conformations. The authors correlate these structural states with transport assays and proton flux measurements, demonstrating that the degree of trapping predicts the potency of each compound in blocking efflux and in potentiating ciprofloxacin activity against NorA-expressing S. aureus.

A particularly striking finding is that the most effective inhibitors act as uncompetitive or state-selective blockers rather than simple competitive antagonists of substrate binding. Because they preferentially bind conformations that the pump visits transiently during its catalytic cycle, their apparent affinity increases when the transporter is actively transporting. This mode of inhibition has important implications for drug design: rather than competing with a diverse array of substrates for a single binding site, next-generation NorA inhibitors can be optimized to exploit the dynamic architecture of the pump, achieving high affinity and selectivity with relatively small molecules.

The study also illuminates the proton-coupling machinery of NorA. Conserved acidic residues in the membrane core, long implicated by mutagenesis in energy coupling, are seen to reposition around the inhibitor-bound cavity, and in some trapped states the ligand directly perturbs the network of polar residues that transmits the proton gradient into mechanical motion. By locking these networks in nonproductive geometries, inhibitors uncouple the pump from its energy source. The authors propose that this uncoupling, rather than physical occlusion alone, underlies the bactericidal synergy observed when inhibitors are combined with fluoroquinolones: the cell expends proton motive force without achieving export, while intracellular drug accumulates to lethal levels.

Beyond NorA itself, the findings carry broad significance for the major facilitator superfamily. Human genomes encode dozens of MFS transporters involved in drug disposition, nutrient uptake, and disease, and pathogenic microbes deploy homologous pumps against nearly every class of antibiotic in clinical use. The principle of conformational trapping, demonstrated here with high-resolution structures and quantitative functional data, provides a transferable design strategy: identify state-selective ligands that bind transient conformations and thereby impose kinetic bottlenecks on the transport cycle. Similar approaches are being explored for other resistance pumps, including members of the resistance-nodulation-division family in Gram-negative pathogens, suggesting a converging theme in anti-efflux drug discovery.

The researchers complemented their experimental work with molecular dynamics simulations that show how inhibitor binding reshapes the free-energy landscape of the transporter. Simulations initiated from inhibitor-bound structures remain confined to the trapped conformations, whereas unliganded NorA samples a broader ensemble of states. Free-energy calculations estimate the stabilization conferred by each ligand and rationalize structure-activity relationships across the inhibitor series. This integration of experiment and computation illustrates how modern structural pharmacology can move from static snapshots to a dynamic, predictive understanding of membrane protein inhibition.

Translational challenges remain before conformational-trapping inhibitors reach the clinic. Efflux pumps such as NorA function within a network of redundant resistance mechanisms, including target modification, enzymatic inactivation, and reduced permeability, so adjuvants will likely need to be combined with optimized antibiotic regimens and, in some cases, with each other. Pharmacokinetic properties, selectivity against human transporters, and the risk of selecting for pump mutations that confer inhibitor resistance all require careful evaluation. Nevertheless, by defining the structural states that small molecules can exploit and demonstrating that state-selective binding translates into potent potentiation of antibiotic activity, the study provides a concrete molecular blueprint. As resistant infections continue to erode the effectiveness of existing drugs, strategies that disarm bacterial pumps at the level of protein dynamics may prove essential to extending the life of the antibiotic arsenal.

Subject of Research: Structural mechanism of NorA efflux pump inhibition by conformational trapping in Staphylococcus aureus

Article Title: Small-molecule inhibitors block NorA efflux by conformational trapping

Article References: Gray, J. L., Ledger, E. V. K., Suwatthee, T., Burden, T. J., Arvaniti, K., Mishra, P., Sefton, A., Papagora, L. E., Clarke, T. B., Riley, J., Pinto, E. G., Cunningham, F., Gilbert, I. H., Gray, D., Wang, D.-N., Read, K. D., Lanyon-Hogg, T., Traaseth, N. J., Edwards, A. M., & Tate, E. W. (2026). Small-molecule inhibitors block NorA efflux by conformational trapping. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02319-6

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02319-6

Keywords: NorA efflux pump, Staphylococcus aureus, major facilitator superfamily, antibiotic adjuvants, conformational trapping, cryo-electron microscopy, fluoroquinolone resistance, proton-coupled transport, efflux pump inhibitors, antimicrobial resistance, Small-molecule, inhibitors